Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study observed that simvastatin promoted hair regrowth in a mouse model of alopecia areata by reducing inflammatory markers and T cell proliferation, partly through disruption of isoprenoid metabolite production.

This study found that the methanolic heartwood extract of Avicennia marina significantly inhibited the enzyme 5 alpha-reductase type 1 in a cell-based assay, suggesting potential anti-androgenic effects for treating androgenic alopecia.

This study reported the development of a scalp serum containing Beta-Sitosterol and nutrient-rich oils, showing stable physicochemical properties, suggesting potential for promoting hair growth and scalp health, though further clinical testing in humans is needed to confirm effectiveness.

This study found that certain bioactive mushroom metabolites may inhibit the enzyme SRD5A2 more effectively than finasteride in computational models, suggesting potential for further research in treating androgenic alopecia.

This research observed that in a prospective case series of 11 women with androgenetic alopecia, oral spironolactone improved hair thinning in most patients over 6 to 36 months, with mild side effects reported. However, effectiveness may be limited in advanced cases.

This study found that one year of antiandrogen treatment with spironolactone significantly decreased bone mineral density in young women with androgen excess.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.

This study found that spironolactone may improve acne and some ovarian functions in patients with irregular menstrual periods and androgenic symptoms, while causing few side effects.

Finasteride effectively lowers specific hormone levels, helping monitor treatment progress.

This study found that four new progesterone derivatives reduced prostate weight in gonadectomized hamsters, suggesting potent in vivo antiandrogenic effects similar to finasteride.

This study found that the dietary supplement RJ-SP4AGA significantly improved hair growth and reduced hair loss in post-menopausal women with androgenetic alopecia over 16 weeks.

This study found that the spermidine analog N1-methylspermidine prolonged hair follicle growth and decreased inflammation and oxidative stress in cultured hair follicles, suggesting potential relevance for treating inflammatory scalp diseases.

This study found that melatonin-loaded vitamin C-based nanovesicles improved hair thickness, density, and reduced hair loss in patients with androgenic alopecia more effectively than melatonin solution.

In this study, low-dose spironolactone reduced the severity of female pattern hair loss in a small group of women without causing significant side effects, suggesting it may be an effective and well-tolerated treatment option.

In this study, two different estroprogestin treatments significantly improved skin conditions and decreased androgen levels in hyperandrogenic women, with EE/DRSP showing more pronounced hormonal changes and skin improvements compared to EE/CMA.

This study suggests that three mushroom-derived bioactive compounds, Zhankuic acid A, Sterenin M, and Melleolide K, may effectively inhibit SRD5A2 and stabilize its interaction, indicating potential for treating androgenic alopecia.

This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.

This abstract reviews the use of spironolactone as a treatment for hormonal acne, female pattern hair loss, and hirsutism due to its antiandrogenic properties and favorable side effect profile, highlighting its value in dermatological therapies.

This study suggests that the neurosteroid allopregnanolone contributes to stress resistance in mice, and the ALLO mimetic drug alfaxalone may offer anxiolytic benefits without muscle-relaxant effects.

This study reports that spironolactone, a potassium-sparing diuretic with antiandrogenic activity, effectively improves hair density, reduces shedding, and stabilizes symptoms in female pattern hair loss, though symptoms often recur after discontinuation, suggesting the need for sustained therapy.

This study found that 60% of men with mild to moderate androgenetic alopecia showed improvement after treatment with botanically derived 5AR inhibitors, suggesting these compounds may be effective, though larger trials are needed.

This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.